HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
- PMID: 29496760
- DOI: 10.1158/1078-0432.CCR-18-0198
HER2 Deregulation in Lung Cancer: Right Time to Adopt an Orphan?
Abstract
HER2-deregulated non-small cell lung cancer is an orphan of any specific therapy, probably because of lack of both accurate patient selection and effective drugs. Recent evidence suggests that osimertinib could be effective in HER2-amplified or mutated lung cancer as a single agent or in combination. Clin Cancer Res; 24(11); 2470-2. ©2018 AACRSee related article by Liu et al., p. 2594.
©2018 American Association for Cancer Research.
Comment on
-
Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib.Clin Cancer Res. 2018 Jun 1;24(11):2594-2604. doi: 10.1158/1078-0432.CCR-17-1875. Epub 2018 Jan 3. Clin Cancer Res. 2018. PMID: 29298799 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
